美股异动 | 治疗乳腺癌药物3期实验显示出积极结果 Celcuity(CELC.US)飙升超210%

智通财经
Jul 28
【美股异动 | 治疗乳腺癌药物3期实验显示出积极结果 Celcuity(CELC.US)飙升超210%】智通财经APP获悉,周一,Celcuity(CELC.US)开盘飙升超210%,一举创历史新高,报41.74美元。消息面上,该公司表示,其药物gedatolisib与fulvestrant联合使用(无论是否添加palbociclib)的3期试验在一种乳腺癌类型中显示出“统计学上显著且具有临床意义”的无进展生存期改善。在该试验中,gedatolisib与fulvestrant和palbociclib联合使用将疾病进展或死亡的风险降低了76%,并将中位无进展生存期延长至9.3个月,而仅使用fulvestrant时为2个月。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10